Literature DB >> 25362195

Identification of Serologic Markers for School-Aged Children With Congenital Rubella Syndrome.

Terri B Hyde1, Helena Keico Sato2, LiJuan Hao1, Brendan Flannery3, Qi Zheng1, Kathleen Wannemuehler1, Flávia Helena Ciccone2, Heloisa de Sousa Marques4, Lily Yin Weckx5, Marco Aurélio Sáfadi6, Eliane de Oliveira Moraes7, Marisa Mussi Pinhata8, Jaime Olbrich Neto9, Maria Cecilia Bevilacqua10, Alfredo Tabith Junior11, Tatiana Alves Monteiro12, Cristina Adelaide Figueiredo13, Jon K Andrus14, Susan E Reef1, Cristiana M Toscano14, Carlos Castillo-Solorzano14, Joseph P Icenogle1.   

Abstract

BACKGROUND: Congenital rubella syndrome (CRS) case identification is challenging in older children since laboratory markers of congenital rubella virus (RUBV) infection do not persist beyond age 12 months.
METHODS: We enrolled children with CRS born between 1998 and 2003 and compared their immune responses to RUBV with those of their mothers and a group of similarly aged children without CRS. Demographic data and sera were collected. Sera were tested for anti-RUBV immunoglobulin G (IgG), IgG avidity, and IgG response to the 3 viral structural proteins (E1, E2, and C), reflected by immunoblot fluorescent signals.
RESULTS: We enrolled 32 children with CRS, 31 mothers, and 62 children without CRS. The immunoblot signal strength to C and the ratio of the C signal to the RUBV-specific IgG concentration were higher (P < .029 for both) and the ratio of the E1 signal to the RUBV-specific IgG concentration lower (P = .001) in children with CRS, compared with their mothers. Compared with children without CRS, children with CRS had more RUBV-specific IgG (P < .001), a stronger C signal (P < .001), and a stronger E2 signal (P ≤ .001). Two classification rules for children with versus children without CRS gave 100% specificity with >65% sensitivity.
CONCLUSIONS: This study was the first to establish classification rules for identifying CRS in school-aged children, using laboratory biomarkers. These biomarkers should allow improved burden of disease estimates and monitoring of CRS control programs. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.

Entities:  

Keywords:  CRS; biomarkers; congenital rubella syndrome; immune response; rubella; serology

Mesh:

Substances:

Year:  2014        PMID: 25362195      PMCID: PMC4654588          DOI: 10.1093/infdis/jiu604

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  25 in total

1.  Gregg's congenital rubella patients 60 years later.

Authors:  Jill M Forrest; Fiona M Turnbull; Gary F Sholler; Richard E Hawker; Frank J Martin; Trevor T Doran; Margaret A Burgess
Journal:  Med J Aust       Date:  2002 Dec 2-16       Impact factor: 7.738

2.  Unseen blindness, unheard deafness, and unrecorded death and disability: congenital rubella in Kumasi, Ghana.

Authors:  J E Lawn; S Reef; B Baffoe-Bonnie; S Adadevoh; E O Caul; G E Griffin
Journal:  Am J Public Health       Date:  2000-10       Impact factor: 9.308

3.  Strategies to eradicate rubella in the English-speaking Caribbean.

Authors:  B Irons; M J Lewis; M Dahl-Regis; C Castillo-Solórzano; P A Carrasco; C A de Quadros
Journal:  Am J Public Health       Date:  2000-10       Impact factor: 9.308

4.  Framework for verifying elimination of measles and rubella.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2013-03-01

5.  Immunoblot analysis of natural and vaccine-induced IgG responses to rubella virus proteins expressed in insect cells.

Authors:  J Nedeljkovic; T Jovanovic; S Mladjenovic; K Hedman; N Peitsaro; C Oker-Blom
Journal:  J Clin Virol       Date:  1999-10       Impact factor: 3.168

6.  Modelling the incidence of congenital rubella syndrome in developing countries.

Authors:  F T Cutts; E Vynnycky
Journal:  Int J Epidemiol       Date:  1999-12       Impact factor: 7.196

7.  Waning antibody levels and avidity: implications for MMR vaccine-induced protection.

Authors:  Mia Kontio; Sari Jokinen; Mikko Paunio; Heikki Peltola; Irja Davidkin
Journal:  J Infect Dis       Date:  2012-09-10       Impact factor: 5.226

8.  Methods of assessing the impact of congenital rubella infection.

Authors:  W A Orenstein; S R Preblud; K J Bart; A R Hinman
Journal:  Rev Infect Dis       Date:  1985 Mar-Apr

9.  Burden of congenital rubella syndrome after a community-wide rubella outbreak, Rio Branco, Acre, Brazil, 2000 to 2001.

Authors:  Tatiana M Lanzieri; T Cristina Segatto; Marilda M Siqueira; Elizabeth C de Oliviera Santos; Li Jin; D Rebecca Prevots
Journal:  Pediatr Infect Dis J       Date:  2003-04       Impact factor: 2.129

10.  Rubella and congenital rubella syndrome control and elimination - global progress, 2000-2012.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2013-12-06       Impact factor: 17.586

View more
  5 in total

Review 1.  Standardization of Assays That Detect Anti-Rubella Virus IgG Antibodies.

Authors:  Wayne Dimech; Liliane Grangeot-Keros; Christelle Vauloup-Fellous
Journal:  Clin Microbiol Rev       Date:  2016-01       Impact factor: 26.132

Review 2.  Does Rubella Cause Autism: A 2015 Reappraisal?

Authors:  Jill Hutton
Journal:  Front Hum Neurosci       Date:  2016-02-01       Impact factor: 3.169

3.  Characterization of rubella-specific humoral immunity following two doses of MMR vaccine using proteome microarray technology.

Authors:  Iana H Haralambieva; Michael J Gibson; Richard B Kennedy; Inna G Ovsyannikova; Nathaniel D Warner; Diane E Grill; Gregory A Poland
Journal:  PLoS One       Date:  2017-11-16       Impact factor: 3.240

4.  Hospital based surveillance of congenital rubella syndrome cases in the pre-vaccine era in Amhara Regional State, Ethiopia: A base line information for the country.

Authors:  Yitayih Wondimeneh; Moges Tiruneh; Getachew Ferede; Kassahun Denekew; Fisseha Admassu; Belay Tessema
Journal:  PLoS One       Date:  2018-11-12       Impact factor: 3.240

5.  Development and Use of an Endpoint Titration Assay To Characterize Mumps IgG Avidity following Measles, Mumps, and Rubella Vaccination and Wild-Type Mumps Infection.

Authors:  Sara Mercader; Marcia McGrew; Sun B Sowers; Nobia J Williams; William J Bellini; Carole J Hickman
Journal:  mSphere       Date:  2018-09-12       Impact factor: 4.389

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.